C.F.R. » Title 21 » CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES › SUBCHAPTER C—DRUGS: GENERAL › PART 201—LABELING › Subpart A—General Labeling Provisions

21 C.F.R. § 201.6

Drugs; misleading statements

Read at: eCFRecfr.gov CornellLII GovInfogovinfo.gov CasesGoogle Scholar

(a) Among representations in the labeling of a drug which render such drug misbranded is a false or misleading representation with respect to another drug or a device or a food or cosmetic.

(b) The labeling of a drug which contains two or more ingredients may be misleading by reason, among other reasons, of the designation of such drug in such labeling by a name which includes or suggests the name of one or more but not all such ingredients, even though the names of all such ingredients are stated elsewhere in the labeling.

[41 FR 6908, Feb. 13, 1976]
Notes of Decisions
Cited in 1 case, 2001–2001 · leading case: Bober, Estelle v. Glaxo Wellcome PLC, 246 F.3d 934 (7th Cir. 2001).
Sort: Relevance Newest Treatment
Bober, Estelle v. Glaxo Wellcome PLC, 246 F.3d 934 (7th Cir. 2001). “57 (c)(3)(v) (prescription labeling); 21 C.F.R. § 201.6 (a) (general labeling).”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.